<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864743</url>
  </required_header>
  <id_info>
    <org_study_id>CTR20210830</org_study_id>
    <nct_id>NCT04864743</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection</brief_title>
  <official_title>An Open-Label, Multicenter Evaluation of the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in Patients With Severe Hemophilia A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Gensciences lnc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Gensciences lnc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to evaluate the Pharmacokinetics，Safety and&#xD;
      tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection&#xD;
      (FRSW117) in patients with severe hemophilia A.&#xD;
&#xD;
      The secondary objectives are to monitor anti-durg antibodies and anti-PEG antibodies levels&#xD;
      in patients with severe hemophilia A&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2 and Arm3..</time_frame>
    <description>Maximum plasma activity during a dosing interval for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - T½ from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>Time required for the activity of the drug to reach half of its original value for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - CL from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>Rate at which the body removes the drug, measured as the volume of the plasma cleared of drug per unit time per unit weight for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - MRT from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 216 hours after the end of the infusion for Arm1; Pre-dose to 288 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>The average time that a drug molecule is present in the systemic circulation for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - Incremental recovery from time 0 to the last data point for FRSW117 Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 216 hours after the end of the infusion forArm1; Pre-dose to 288 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>The rise in FVIII activity in IU/dL per unit dose administered in IU/kg for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - Cmax from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>Maximum plasma activity during a dosing interval for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - T½ from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>Time required for the activity of the drug to reach half of its original value for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - CL from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>Rate at which the body removes the drug, measured as the volume of the plasma cleared of drug per unit time per unit weight for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - MRT from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>The average time that a drug molecule is present in the systemic circulation for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm1 - Incremental recovery from time 0 to the last data point for ADVATE Measured by One-Stage Clotting Assay.</measure>
    <time_frame>Pre-dose to 72 hours after the end of the infusion for Arm1; Pre-dose to120 hours after the end of the infusion for Arm2 and Arm3.</time_frame>
    <description>The rise in FVIII activity in IU/dL per unit dose administered in IU/kg for participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs).</measure>
    <time_frame>assessed up to four weeks after FRSW117 administration.</time_frame>
    <description>Adverse events in the study were classified and evaluated according to the National Cancer Institute's Common Terminology for Adverse Events (NCI CTCAE V5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the level of anti-PEG-rFⅧFc antibody production in participants</measure>
    <time_frame>assessed up to four weeks after FRSW117 administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the level of anti-PEG antibody production in participants</measure>
    <time_frame>assessed up to four weeks after FRSW117 administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with inhibitor development.</measure>
    <time_frame>assessed up to four weeks after FRSW117 administration.</time_frame>
    <description>Number of participants who developed a positive FVIII inhibitor level (≥0.6 Bethesda unit [BU]) during the study was summarized and classified as participants developing low titer inhibitor (i.e. ≤ 5.0 BU) and participants developing high titer inhibitor (i.e. &gt; 5.0 BU).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Severe Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Arm 1-ADVATE+FRSW117(25 IU/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two treatments: 25 IU/kg ADVATE in the first period, followed by 25 IU/kg FRSW117 in the second period, with a washout period before each treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2-ADVATE+FRSW117( 50 IU/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW117 in the second period, with a washout period before each treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3-ADVATE+FRSW117(65 IU/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two treatments: 65 IU/kg ADVATE in the first period, followed by 65 IU/kg FRSW117 in the second period, with a washout period before each treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADVATE</intervention_name>
    <description>a single dose.</description>
    <arm_group_label>Arm 1-ADVATE+FRSW117(25 IU/kg)</arm_group_label>
    <arm_group_label>Arm 2-ADVATE+FRSW117( 50 IU/kg)</arm_group_label>
    <arm_group_label>Arm 3-ADVATE+FRSW117(65 IU/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FRSW117</intervention_name>
    <description>a single dose.</description>
    <arm_group_label>Arm 1-ADVATE+FRSW117(25 IU/kg)</arm_group_label>
    <arm_group_label>Arm 2-ADVATE+FRSW117( 50 IU/kg)</arm_group_label>
    <arm_group_label>Arm 3-ADVATE+FRSW117(65 IU/kg)</arm_group_label>
    <other_name>PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically confirmed hemophilia A (coagulation factor VIII &lt;1%) and&#xD;
             previous medical records confirming exposure to coagulation factor VIII for ≥150 days&#xD;
             (EDs ≥150).&#xD;
&#xD;
          -  Non-immunodeficient, with some immunity (CD4 &gt; 200/μL).&#xD;
&#xD;
          -  Platelet count &gt;100×10^9/L.&#xD;
&#xD;
          -  Normal prothrombin time (PT) or international normalized ratio (INR) &lt;1.3.&#xD;
&#xD;
          -  Negative lupus anticoagulant.&#xD;
&#xD;
          -  Fully understand, informed about this study and sign the informed consent form,&#xD;
             voluntarily participate in the clinical study and have the ability to complete all&#xD;
             study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to the test substance or its excipients (including rodent or hamster&#xD;
             protein).&#xD;
&#xD;
          -  Pre-existing hypersensitivity or allergic reactions to FVIII or IgG2 injection&#xD;
             therapy.&#xD;
&#xD;
          -  Positive FVIII inhibitor at screening (≥0.6 BU/mL), or previous history of FVIII&#xD;
             inhibitor Positive history, or family history of inhibitors.&#xD;
&#xD;
          -  Patients with other coagulation disorders in addition to hemophilia A.&#xD;
&#xD;
          -  The results of vWF antigen examination lower than normal.&#xD;
&#xD;
          -  Severe anemia and need blood transfusion (hemoglobin &lt; 60g/L).&#xD;
&#xD;
          -  Patients who have received any standard half-lives FVIII formulations (e.g., Kogenate,&#xD;
             Kovaltry, Advate, Xyntha, etc.) or received any other half-life-extending FVIII&#xD;
             formulations within 4 days or 5 half-lives (whichever is longer) before&#xD;
             administration.&#xD;
&#xD;
          -  Patients who had used emecizumab within 6 months prior to administration.&#xD;
&#xD;
          -  Patients with fever, upper respiratory tract infection or allergy symptoms within the&#xD;
             previous 2 weeks before screening.&#xD;
&#xD;
          -  Suffer from other diseases that may increase the risk of bleeding or the risk of&#xD;
             thrombosis.&#xD;
&#xD;
          -  Severe cardiovascular and cerebrovascular diseases: such as cerebral hemorrhage,&#xD;
             stroke, myocardial infarction, unstable angina pectoris, congestive heart failure(the&#xD;
             current New York Heart Association cardiac function grade III, Hypertension that&#xD;
             cannot be controlled with drug treatment: systolic blood pressure&gt; 160 mmHg or&#xD;
             diastolic blood pressure&gt; 95 mmHg.&#xD;
&#xD;
          -  Clinically significant of other systematic diseases: alcoholism, drug abuse, mental&#xD;
             disorders and mental retardation.&#xD;
&#xD;
          -  Significant hepatic or renal impairment (ALT and AST &gt; 2×ULN; serum bilirubin level &gt;&#xD;
             3 × upper limit of normal (ULN)).&#xD;
&#xD;
          -  Abnormal kidney function: BUN &gt; 2×ULN, Cr &gt; 2.0mg/dL.&#xD;
&#xD;
          -  One or more clinically significant tests for Hepatitis B Virus Surface Antigen, Human&#xD;
             Immunodeficiency Virus (HIV), Antisyphilitic spirulina (TPHA) and Hepatitis C Virus&#xD;
             (HCV) Antibody.&#xD;
&#xD;
          -  Patients who received any anticoagulant or antiplatelet therapy within a week prior&#xD;
             screening or need to receive an anticoagulant or antiplatelet therapy during the&#xD;
             period of clinical trials.&#xD;
&#xD;
          -  Systemic immunomodulators (e.g., corticosteroids [equivalent dose of 10 mg/ day&#xD;
             prednisone], A-interferon, immunoglobulin, cyclophosphamide, cyclosporine, etc.) were&#xD;
             used within 14 days prior to administration or during the study period.&#xD;
&#xD;
          -  Patients having major surgery or receiving blood or blood components transfusion&#xD;
             within 4 weeks prior screening or having planned major surgery schedule during the&#xD;
             study.&#xD;
&#xD;
          -  Patients who previously participated in the other clinical trials within a month prior&#xD;
             screening.&#xD;
&#xD;
          -  Any life-threatening disease or condition which, according to the investigator's&#xD;
             judgment, could not benefit from the trial participation.&#xD;
&#xD;
          -  Patient who is considered by the other investigators not suitable for clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renchi Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weichuan Mo</last_name>
    <phone>+86-010-67806990</phone>
    <email>weichuanmo@gensciences.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuxia Guo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan central hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Chen</last_name>
    </contact>
    <contact_backup>
      <last_name>Qing Wen</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College.</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renchi Yang, PhD</last_name>
      <email>rcyang65@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe Hemophilia A</keyword>
  <keyword>PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Efficacy and tolerability</keyword>
  <keyword>Phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

